Sign In

Study

Recurrence, Treatment, and Complication Patterns of Intermediate Risk Non-muscle Invasive Bladder Cancer

This study will comprehensively assess the clinical course of intermediate risk non-muscle invasive bladder cancer (NMIBC) in 291 patients diagnosed at Kaiser Permanente Northern California who are enrolled in the Be-Well Study. Intermediate risk NMIBC is an understudied form of one of the most common urologic cancers in the U.S. We will examine recurrence and progression patterns of intermediate risk NMIBC; determine complications associated with its diagnosis and treatment; and characterize healthcare utilization related to its surveillance.
Investigator: Kwan, Marilyn
Funder: UroGen Pharma, Inc.